Navamedic ASA (FRA:N1A)

Market Cap	44.62M +44.3%
Revenue (ttm)	50.87M +6.4%
Net Income	-1.44M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	102.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1
Open	1.825
Previous Close	1.945
Day's Range	1.825 - 1.825
52-Week Range	1.660 - 2.180
Beta	n/a
RSI	67.28
Earnings Date	Aug 14, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 38
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: N1A

Financial Performance

In 2025, Navamedic ASA's revenue was 565.36 million, an increase of 6.38% compared to the previous year's 531.44 million. Losses were -23.54 million, 329.1% more than in 2024.

Financial numbers in NOK